Literature DB >> 25661347

Smac is another pathway in the anti-tumour activity of Trichosanthin and reverses Trichosanthin resistance in CaSki cervical cancer cells.

Lei Cui1, Jian Song2, Liting Wu3, Liming Huang3, Yanlin Wang3, Yingdi Huang3, Han Yu3, Yiling Huang3, C C You3, Jiayou Ye3.   

Abstract

Trichosanthin (TCS), or Tin Hua Fen, is a renowned traditional Chinese medicine and is still used in Chinese clinics for midterm abortion and the treatment of choriocarcinoma. Many studies have demonstrated that TCS has anti-tumour action as a type I ribosome-inactivating protein. We hypothesized that there is another pathway of the anti-tumour activity of TCS. cDNA array analysis was applied to profile changes in gene expression of human CaSki in response to TCS stimulation. Smac, a mitochondrial protein, was identified as the highly upregulated protein in response to TCS treatment. The mRNA and protein levels of Smac were determined by real-time RT-PCR and Western blotting respectively. We analysed the methylation status of Smac using methylation-specific PCR (MSP) and indicates that TCS promotes Smac demethylation and increases its expression in cervical CaSki cells. Tumour cells develop resistance to TCS during prolonged treatment, as with other classic chemotherapeutic agents. Smac expression was downregulated and Twist was upregulated in TCS-resistant cells. These results indicate that TCS has demethylating activity and that Smac is involved in both TCS response and TCS resistance.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-tumour activity; Smac; Trichosanthin

Mesh:

Substances:

Year:  2014        PMID: 25661347     DOI: 10.1016/j.biopha.2014.10.027

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

Review 1.  Advances on Tumor-Targeting Delivery of Cytotoxic Proteins.

Authors:  Akmal M Asrorov; Zeyun Gu; Kyoung Ah Min; Meong Cheol Shin; Yongzhuo Huang
Journal:  ACS Pharmacol Transl Sci       Date:  2019-12-30

2.  Trichosanthin suppresses the proliferation of glioma cells by inhibiting LGR5 expression and the Wnt/β-catenin signaling pathway.

Authors:  Junjie Miao; Yilin Jiang; Dongliang Wang; Jingru Zhou; Cungang Fan; Feng Jiao; Bo Liu; Jun Zhang; Yangshuo Wang; Qingjun Zhang
Journal:  Oncol Rep       Date:  2015-09-18       Impact factor: 3.906

Review 3.  The Progress of Methylation Regulation in Gene Expression of Cervical Cancer.

Authors:  Chunyang Feng; Junxue Dong; Weiqin Chang; Manhua Cui; Tianmin Xu
Journal:  Int J Genomics       Date:  2018-04-16       Impact factor: 2.326

Review 4.  Structural and Functional Investigation and Pharmacological Mechanism of Trichosanthin, a Type 1 Ribosome-Inactivating Protein.

Authors:  Wei-Wei Shi; Kam-Bo Wong; Pang-Chui Shaw
Journal:  Toxins (Basel)       Date:  2018-08-20       Impact factor: 4.546

Review 5.  Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents.

Authors:  Akmal M Asrorov; Bahtiyor Muhitdinov; Bin Tu; Sharafitdin Mirzaakhmedov; Huiyuan Wang; Yongzhuo Huang
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

Review 6.  Engineering of Ribosome-inactivating Proteins for Improving Pharmacological Properties.

Authors:  Jia-Qi Lu; Zhen-Ning Zhu; Yong-Tang Zheng; Pang-Chui Shaw
Journal:  Toxins (Basel)       Date:  2020-03-09       Impact factor: 4.546

Review 7.  A Sixty-Year Research and Development of Trichosanthin, a Ribosome-Inactivating Protein.

Authors:  Jia-Qi Lu; Kam-Bo Wong; Pang-Chui Shaw
Journal:  Toxins (Basel)       Date:  2022-02-27       Impact factor: 4.546

8.  Trichosanthin inhibits cervical cancer by regulating oxidative stress-induced apoptosis.

Authors:  Chenglu Zhu; Cuilan Zhang; Xiaoming Cui; Jing Wu; Zhizhu Cui; Xiaojuan Shen
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.